Literature DB >> 16169422

Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the Live-Enox study.

Benjamin Brenner1, Jacob Bar, Martin Ellis, Ilan Yarom, David Yohai, Aaron Samueloff.   

Abstract

Women with thrombophilia and a history of recurrent pregnancy loss have poor pregnancy outcomes. Prophylaxis with enoxaparin 40 mg/day or 80 mg/day resulted in favorable gestational and neonatal outcomes.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16169422     DOI： 10.1016/j.fertnstert.2005.03.048

Source DB:  PubMed          Journal:  Fertil Steril        ISSN： 0015-0282            Impact factor:   7.329


  8 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia.

Authors:  Paulien G de Jong; Stef Kaandorp; Marcello Di Nisio; Mariëtte Goddijn; Saskia Middeldorp
Journal:  Cochrane Database Syst Rev       Date:  2014-07-04

Review 3.  Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period.

Authors:  Rebecca Tooher; Simon Gates; Therese Dowswell; Lucy-Jane Davis
Journal:  Cochrane Database Syst Rev       Date:  2010-05-12

4.  Care prior to and during subsequent pregnancies following stillbirth for improving outcomes.

Authors:  Aleena M Wojcieszek; Emily Shepherd; Philippa Middleton; Zohra S Lassi; Trish Wilson; Margaret M Murphy; Alexander Ep Heazell; David A Ellwood; Robert M Silver; Vicki Flenady
Journal:  Cochrane Database Syst Rev       Date:  2018-12-17

5.  Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period.

Authors:  Philippa Middleton; Emily Shepherd; Judith C Gomersall
Journal:  Cochrane Database Syst Rev       Date:  2021-03-29

6.  ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia--study protocol for a randomized controlled trial.

Authors:  Paulien G de Jong; Siobhan Quenby; Kitty W M Bloemenkamp; Babette A M Braams-Lisman; Jan Peter de Bruin; Arri Coomarasamy; Michele David; Maria T DeSancho; Olivier W H van der Heijden; Annemieke Hoek; Barbara A Hutten; Kristin Jochmans; Carolien A M Koks; Walter K M Kuchenbecker; Ben Willem J Mol; Helen L Torrance; Hubertina C J Scheepers; Mary D Stephenson; Harold R Verhoeve; Jantien Visser; Johanna I P de Vries; Mariëtte Goddijn; Saskia Middeldorp
Journal:  Trials       Date:  2015-05-07       Impact factor: 2.279

7.  Comparison of two preventive treatments for patients with recurrent miscarriages carrying a C677T methylenetetrahydrofolate reductase mutation: 5-year experience.

Authors:  Philippe Merviel; Rosalie Cabry; Emmanuelle Lourdel; Segolene Lanta; Carole Amant; Henri Copin; Moncef Benkhalifa
Journal:  J Int Med Res       Date:  2017-01-12       Impact factor: 1.671

8.  Aspirin and low-molecular weight heparin combination therapy effectively prevents recurrent miscarriage in hyperhomocysteinemic women.

Authors:  Pratip Chakraborty; Sayani Banerjee; Piyali Saha; Shyam Sundar Nandi; Sunita Sharma; Sourendra K Goswami; Baidyanath Chakravarty; Syed N Kabir
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.